Innovative Diagnostic Platform Cleveland Diagnostics has developed the IsoClear™ platform, leveraging protein structure for novel diagnostics, positioning it as a leader in cutting-edge diagnostic technologies that appeal to labs seeking advanced, structure-based testing solutions.

Regulatory Milestone With FDA approval for the IsoPSA test for prostate cancer, the company demonstrates its ability to meet stringent regulatory standards, opening avenues for nationwide sales and increased adoption in clinical laboratories and healthcare providers.

Market Expansion Recent leadership hires and a strong focus on commercial expansion, including launching a prostate cancer awareness campaign, suggest active efforts to grow market presence and customer base in the prostate cancer diagnostics space.

Financial Strength Cleveland Diagnostics secured $75 million in financing and generates annual revenue estimated between $25 million and $50 million, providing resources to scale operations, foster partnerships, and increase sales outreach.

Strategic Collaborations The favorable Medicare coverage decision and assigned CPT code for IsoPSA facilitate reimbursement prospects and could accelerate sales growth by making the test more accessible to Medicare beneficiaries and healthcare systems nationwide.